<SEC-DOCUMENT>0001104659-22-042500.txt : 20220804
<SEC-HEADER>0001104659-22-042500.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220405060627
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-22-042500
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 240px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman Pepper
    Hamilton Sanders LLP</FONT></TD>
    <TD ROWSPAN="5" STYLE="border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="tm229830d3_drsltrimg001.jpg" ALT=""></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">401 9th Street, NW, Suite&nbsp;1000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington, DC 20004</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">troutman.com&nbsp;</FONT></P>
                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Thomas
M. Rose</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">757-687-7715</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">thomas.rose@troutman.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>VIA
EDGAR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
States Securities and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
of Life Sciences</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
DC 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Michael Davis, Jeffrey Gabor, Gary Newberry and Jeanne Baker</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B>Re:</FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProMIS
    Neurosciences Inc.<BR>
    Draft Registration Statement on Form&nbsp;10</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Submitted
    January&nbsp;28, 2022<BR>
    CIK No.&nbsp;0001374339</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of our client, ProMIS Neurosciences&nbsp;Inc. (the &ldquo;<B>Company</B>&rdquo;), we submit this letter in response to the comments
from the staff of the U.S. Securities and Exchange Commission&rsquo;s (the &ldquo;<B>Commission</B>&rdquo;) Division of Corporation Finance
(the &ldquo;<B>Staff</B>&rdquo;) received by letter dated February&nbsp;25, 2022 (the &ldquo;<B>Staff Letter</B>&rdquo;) relating to
the Company&rsquo;s Draft Registration Statement on Form&nbsp;10 (CIK No.&nbsp;0001374339) (the &ldquo;<B>Registration Statement</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is concurrently filing Amendment No.&nbsp;1 to the Registration Statement (&ldquo;<B>Amendment No.&nbsp;1</B>&rdquo;), which
reflects changes made in response to the Staff Letter and certain other changes. Based on a recent announcement by the Staff, we have
not mailed to the Commission&rsquo;s offices any courtesy copies of this response letter or marked copies of Amendment No.&nbsp;1 showing
all changes from the Registration Statement. Nevertheless, should you desire for us to do so, please advise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
ease of reference, we have incorporated the comments from the Staff Letter into this letter in italics, numbered to correspond to the
numbering used in the Staff Letter and followed by the Company&rsquo;s response. Capitalized terms used in this letter but not otherwise
defined herein shall have the meanings set forth in Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page&nbsp;2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Draft
Registration Statement on Form&nbsp;10, Submitted January&nbsp;28, 2022</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item
1. Business</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Our
Pipeline, page&nbsp;2</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>1.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                            note that your pipeline table on page&nbsp;2 includes three separate pre-clinical phases
                                            but none of the three clinical phases. This gives the impression that your product candidates
                                            are farther along in the clinical process. Please revise your pipeline table to include separate
                                            columns for each of the three clinical phases. Please also explain what is involved in &ldquo;epitope
                                            prediction/computation&rdquo; and &ldquo;in vitro/in vivo lead validation&rdquo; and why
                                            you believe these are separate and distinct development phases, as opposed to part of discovery
                                            and/or IND-enabling studies, or revise. In addition, revise the length of the arrows for
                                            each product candidate to accurately show its progression in relation to each stage of development
                                            once the table has been revised. Please also make similar revisions to the Additional Development
                                            Programs table on page&nbsp;3.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on pages&nbsp;2 and 3 of Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PMN310,
page&nbsp;4</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                            note on page&nbsp;4 that you state you &ldquo;believe it may possess the features necessary
                                            to potentially be &lsquo;best in class&rsquo; if approved, with a possibly more favorable
                                            clinical safety and efficacy profile than aducanumab, donanemab, or BAN2401.&rdquo; On page&nbsp;22
                                            you also state that &ldquo;[t]hese drug development tools are called peptide antigens and
                                            are the key to our efficient methods of creating potentially &lsquo;best in class&rsquo;
                                            antibody therapies, vaccines, and diagnostics.&rdquo; Please remove any reference to your
                                            product(s)&nbsp;potentially being &ldquo;best in class.&rdquo; This phrase suggests that
                                            your product candidates are effective and likely to be approved. Please also delete any reference
                                            to your product(s)&nbsp;possibly being safe and efficacious. Safety and efficacy determinations
                                            are solely within the FDA&rsquo;s authority.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In response to the Staff&rsquo;s comment, the Company has
revised its disclosure on pages&nbsp;5, 8, 15, 16, 24, 41 and 90 of Amendment No.&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                            note the disclosure throughout this section stating that the &ldquo;latest scientific understanding
                                            that the toxic oligomer is the pathogen and needs to be the target for therapy&rdquo; and
                                            &ldquo;[e]vidence from genetic and experimental studies supports a causative role for Ab
                                            in the pathogenesis of AD.&rdquo; Please revise these and similar statements to clearly describe
                                            the basis for this scientific understanding and where evidence was observed and whether it
                                            was based on studies or trials conducted by you or by a third party.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page&nbsp;3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on pages&nbsp;4, 5, 6, 7 and 22 of Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                            note your statement that the &ldquo;latest scientific understanding that the toxic oligomer
                                            is the pathogen and needs to be the target for therapy.&rdquo; Please revise/balance this
                                            disclosure by stating that there &ldquo;is no current scientific or general consensus on
                                            the causation of AD or method of action to treat AD&rdquo; as disclosed in your risk factor
                                            on page&nbsp;37.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;5 of Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>For
                                       each of the preclinical trials discussed in this section, please revise to clarify scope, size,
                                       and design; whether the studies were powered to show statistical significance; and revise your
                                       characterizations of the pre-clinical trials to discuss the data, rather than drawing conclusions
                                       from the results.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In response to the Staff&rsquo;s comment, the Company has
revised its disclosure on pages&nbsp;6, 7, 9 and 10 of Amendment No.&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview
of ProMIS Intellectual Property (IP) Portfolio, page&nbsp;23</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>6.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
                                            expand your disclosure to describe all material terms of your license agreements with University
                                            of British Columbia and University Hospital Network, including:</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>description
                                            and quantification of the benefits and obligations under the agreement,</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>quantification
                                            of all payments made to date,</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>disclosure
                                            of the aggregate amount of all potential development, regulatory and commercial milestone
                                            payments,</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>quantification
                                            of the royalty rate, or a range no greater than 10 percentage points per tier, and</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>term
                                            and termination provisions.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In response to the Staff&rsquo;s comment, the Company has
revised its disclosure on page&nbsp;26 of Amendment No.&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page&nbsp;4</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>7.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>For
                                            each material patent and patent application, please revise to clarify whether the patents
                                            are owned or licensed, the type of patent protections, and the expiration dates.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;25 of Amendment No.&nbsp;1 and has added a summary of its patent portfolio in Appendix A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Competition,
page&nbsp;33</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>We
                                            note your disclosure regarding neurodegenerative disease key competitors. Please revise to
                                            provide more robust disclosure regarding the potential impact on the company of these key
                                            competitors, including whether any are developing therapies with AB/amyloid plaque-related
                                            targets or whether any have received approval from the FDA. In this regard, we note the risk
                                            factor disclosure on page&nbsp;76.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In response to the Staff&rsquo;s comment, the Company has
revised its disclosure on page&nbsp;37 of Amendment No.&nbsp;1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item
1A. Risk Factors, page&nbsp;33</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
                                            reference to your disclosure on page&nbsp;114, please revise to add a risk factor that addresses
                                            your ability to issue an unlimited number of common and preferred shares.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;81 of Amendment No.&nbsp;1 to add a risk
factor addressing the Company&rsquo;s ability to issue an unlimited number of common and preferred shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Risks
Related to the COVID-19 Pandemic, page&nbsp;33</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>10.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
                                        revise here or elsewhere to quantify the specific impacts you have experienced to your business
                                        and results of operations resulting from the COVID-19 pandemic.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;37 of Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White"><B>Securities
and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">April
5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Page&nbsp;5</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual
property discovered through government funded programs may be subject to federal regulations such as march-in rights, page&nbsp;69</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>11.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
                                        revise to identify the patents and product candidates that are or may be subject to march-in
                                        rights.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;73 of Amendment No.&nbsp;1. We have been
advised by the Company that as of the date of Amendment No.&nbsp;1, neither its patents nor its product candidates are subject to march-in
rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Management&rsquo;s
Discussion and Analysis</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Results
of Operations -- Research and Development, page&nbsp;88</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>12.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
                                            expand your disclosure to identify the program(s)&nbsp;under which you incurred material
                                            research and development expenses and quantify the respective amounts for each period presented.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;92 of Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Item
4. Security Ownership of Certain Beneficial Owners and Management, page&nbsp;93</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>13.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
                                        disclose the natural person or persons who exercise the voting and/or dispositive powers with
                                        respect to the securities owned by Title 19 Investments LLC and Crocker Mountain LLC.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on page&nbsp;98 of Amendment No.&nbsp;1 to disclose the
natural persons who exercise voting and/or dispositive powers with respect to securities owned by Title 19 Investments LLC and Crocker
Mountain LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;Index,
page&nbsp;119</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>14.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please
                                            revise your Business section to provide a description of your joint venture agreement(s)&nbsp;with
                                            BC Neuroimmunology Lab Inc. Please include a discussion of the specific contractual terms
                                            of your joint venture agreement(s)&nbsp;and the degree of your involvement in operating the
                                            joint ventures.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RESPONSE</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the Staff&rsquo;s comment, the Company has revised its disclosure on pages&nbsp;25 and 26 of Amendment No.&nbsp;1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White"><B>Securities
and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">April
5, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141b4d"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: White">Page&nbsp;6</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thank
you for your consideration of the Company&rsquo;s response. If you have any questions or require additional information, please do not
hesitate to contact me at the phone number or address set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Thomas M. Rose</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas M. Rose,&nbsp;Esq.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Williams, Chairman and Chief Executive Officer</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS Neurosciences&nbsp;Inc.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm229830d3_drsltrimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm229830d3_drsltrimg001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, *L# 2(  A$! Q$!_\0
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MXN4RVVKW(NS$P/F%3%N#'(^?OV]41/\ @KI^Q$0%\H:7\!VF51PY_P"%Z>/
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ME4SK@C@3P=X1J<*\*2XKXL<:<I\4U7.I4_XRA.M4@DN=U>=^S=**G&$8./\
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M&O&HDFI4</#(:2LFU%QI8-7C=M.33O9,_*?_ (*'_L'>/?VF?$?PF^,7P/\
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M'.N#.?NC':OV%_X+*?\ !<']CW]J_P#8L\;_ +,'[.FL>,?'7BOXL^(_A_\
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M)#;LN8;>.V5+<(HB)P5'KN?0 ?AG^>:C9W!(#$ >G^?Y5V.OB9ZN6CUUF_\
MVU+\S:IB\SQ"7ML?6GU5Y3GKJKWG4FT[=4T[-ZG&>"? ?@GX;>']/\)^ O"'
MAWP+X5T8:DVF>&/!VA:7X>\.6#:OJ3ZQJ[Z1H.@Q106GFZS/)/<1000QB>:1
0E1RQD;OJ**YCE"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
